Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer

References

• Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73(7):202. doi:10.1158/0008-5472.CAN-12-1699
   Web of Science ®Google Scholar
• Howard FM, Olopade OI. Triple-negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245–1261. doi:10.3892/ijo.2020.5135
   PubMed Web of Science ®Google Scholar
• Won KA, Spruck C. Triple-negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245–1261.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI45014
   PubMed Web of Science ®Google Scholar
• Nedeljković M, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019;8(9):957. doi:10.3390/cells8090957
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Hwang S-Y, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019;199:30–57. doi:10.1016/j.pharmthera.2019.02.006
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. doi:10.1186/s13045-022-01341-0
   PubMed Web of Science ®Google Scholar
• MacDonald I, Nixon NA, Khan OF. Triple-negative breast cancer: a review of current curative intent therapies. Curr Oncol. 2022;29(7):4768–4778. doi:10.3390/curroncol29070378
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Esposito A, Trapani D, et al. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treat Rev. 2016;50:205–207. doi:10.1016/j.ctrv.2016.09.019
   PubMed Web of Science ®Google Scholar
• Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–569. doi:10.1200/JCO.18.01010
   PubMed Web of Science ®Google Scholar
• Benci JL, Johnson LR, Choa R, et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell. 2019;178(4):933–948. doi:10.1016/j.cell.2019.07.019
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng P. Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy. Trends Pharmacol Sci. 2020;41(1):4–12. doi:10.1016/j.tips.2019.11.003
   PubMed Web of Science ®Google Scholar
• Retecki K, Seweryn M, Graczyk-Jarzynka A, et al. The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance. Cancers. 2021;13(23):6012. doi:10.3390/cancers13236012
   PubMed Web of Science ®Google Scholar
• Wang A, Yang X, Li R, et al. Immunomodulator-mediated suppressive tumor immune microenvironment remodeling nanoplatform for enhanced immuno/chemo/photothermal combination therapy of triple negative breast cancer. ACS Appl Mater Interfaces. 2023;15(46):53318–53332. doi:10.1021/acsami.3c14137
   PubMed Web of Science ®Google Scholar
• Jing ZH, Li YF, Song JX, et al. Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes. Int J Biol Macromol. 2023;253(Pt 3):126912. doi:10.1016/j.ijbiomac.2023.126912
   PubMedGoogle Scholar
• Mo XP, Zheng ZN, He Y, et al. Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide. J Control Release. 2018;287:12–23. doi:10.1016/j.jconrel.2018.08.012
   PubMed Web of Science ®Google Scholar
• Yang YC, Tian Q, Wu SQ, et al. Blue light-triggered Fe2+-release from monodispersed ferrihydrite nanoparticles for cancer iron therapy. Biomaterials. 2021;271:120739.
   PubMed Web of Science ®Google Scholar
• Tang K, Wang B, Yu B, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy. Eur J Med Chem. 2022;227:113967. doi:10.1016/j.ejmech.2021.113967
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang B, Liu J, et al. An overview on the methods of determining the activity of Indoleamine 2, 3-Dioxygenase 1. J Drug Target. 2019;27:724–731.
   PubMed Web of Science ®Google Scholar
• Zhai L, Ladomersky E, Lenzen A, et al. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018;15(5):447–457. doi:10.1038/cmi.2017.143
   PubMed Web of Science ®Google Scholar
• Newman AC, Falcone M, Huerta Uribe A, et al. Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells. Mol Cell. 2021;81:2290–2302.e7.
   PubMed Web of Science ®Google Scholar
• Li F, Zhang R, Li S, et al. IDO1: an important immunotherapy target in cancer treatment. Int Immunopharmacol. 2017;47:70–77. doi:10.1016/j.intimp.2017.03.024
   PubMed Web of Science ®Google Scholar
• Kraehenbuehl L, Weng CH, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19:37–50.
   PubMed Web of Science ®Google Scholar
• Li F, Zhao Y, Wei L, et al. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther. 2018;19(8):695–705. doi:10.1080/15384047.2018.1450116
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Kato S, Nesline MK, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461. doi:10.1016/j.ctrv.2022.102461
   PubMed Web of Science ®Google Scholar
• Song X, Si Q, Qi R, et al. Indoleamine 2, 3-Dioxygenase 1: a promising therapeutic target in malignant tumor. Front Immunol. 2021;12:800630. doi:10.3389/fimmu.2021.800630
   PubMed Web of Science ®Google Scholar
• Kenski JCN, Huang X, Vredevoogd DW, et al. An adverse tumor-protective effect of IDO1 inhibition. Cell Rep Med. 2023;4(2):100941. doi:10.1016/j.xcrm.2023.100941
   PubMedGoogle Scholar
• Kroemer G, Galassi C, Zitvogel L, et al. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2
   PubMed Web of Science ®Google Scholar
• Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994–3006. doi:10.1002/1878-0261.12851
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang G, Chen Y, et al. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23(8):4854–4865. doi:10.1111/jcmm.14356
   PubMed Web of Science ®Google Scholar
• Zhu M, Yang M, Zhang J, et al. Immunogenic cell death induction by ionizing radiation. Front Immunol. 2021;12:705361. doi:10.3389/fimmu.2021.705361
   PubMed Web of Science ®Google Scholar
• Alzeibak R, Mishchenko TA, Shilyagina NY, et al. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer. 2021;9(1):e001926. doi:10.1136/jitc-2020-001926
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. doi:10.1038/nrc3380
   PubMed Web of Science ®Google Scholar
• Xu M, Lu JH, Zhong YZ, et al. Immunogenic cell death-relevant damage-associated molecular patterns and sensing receptors in triple-negative breast cancer molecular subtypes and implications for immunotherapy. Front Oncol. 2022;12:870914. doi:10.3389/fonc.2022.870914
   PubMed Web of Science ®Google Scholar
• Hayashi K, Nikolos F, Lee YC, et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun. 2020;11(1):6299. doi:10.1038/s41467-020-19970-9
   PubMed Web of Science ®Google Scholar
• Jiang M, Zeng J, Zhao L, et al. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy. Nanoscale. 2021;13(41):17218–17235. doi:10.1039/D1NR05512G
   PubMed Web of Science ®Google Scholar
• Qi J, Jin F, You Y, et al. Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles. Nat Commun. 2021;12(1):4755. doi:10.1038/s41467-021-24902-2
   PubMed Web of Science ®Google Scholar
• Lau TS, Chan LKY, Man GCW, et al. Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis. Cancer Immunol Res. 2020;8(8):1099–1111. doi:10.1158/2326-6066.CIR-19-0616
   PubMed Web of Science ®Google Scholar
• Abdel-Bar HM, Walters AA, Lim Y, et al. An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors. Theranostics. 2021;11(18):8738–8754. doi:10.7150/thno.56936
   PubMed Web of Science ®Google Scholar
• Song JX, Cheng MY, Xie Y, et al. Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug. J Nanobiotechnology. 2023;21(1):93.
   PubMed Web of Science ®Google Scholar
• Banstola A, Poudel K, Kim JO, et al. Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death. J Control Release. 2021;337:505–520. doi:10.1016/j.jconrel.2021.07.038
   PubMed Web of Science ®Google Scholar
• Zuo H, Tao J, Wang M, et al. A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles. RSC Adv. 2022;12(43):28104–28112. doi:10.1039/D2RA04326B
   PubMed Web of Science ®Google Scholar
• Li Y, Qiao K, Zhang X, et al. Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor. iScience. 2021;24(12):103392. doi:10.1016/j.isci.2021.103392
   PubMed Web of Science ®Google Scholar
• Xia C, Li M, Ran G, et al. Redox-responsive nanoassembly restrained myeloid-derived suppressor cells recruitment through autophagy-involved lactate dehydrogenase A silencing for enhanced cancer immunochemotherapy. J Control Release. 2021;335:557–574. doi:10.1016/j.jconrel.2021.05.034
   PubMed Web of Science ®Google Scholar
• Birmpilis AI, Paschalis A, Mourkakis A, et al. Immunogenic cell death, DAMPs and prothymosin α as a putative anticancer immune response biomarker. Cells. 2022;11(9):1415. doi:10.3390/cells11091415
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhao P, Luo Z, et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10(11):10049–10057. doi:10.1021/acsnano.6b04695
   PubMed Web of Science ®Google Scholar
• Jiang Y, Krishnan N, Zhou J, et al. Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity. Adv Mater. 2020;32(30):e2001808. doi:10.1002/adma.202001808
   PubMed Web of Science ®Google Scholar
• Serpooshan V, Sheibani S, Pushparaj P, et al. Effect of cell sex on uptake of nanoparticles: the overlooked factor at the nanobio interface. ACS Nano. 2018;12(3):2253–2266. doi:10.1021/acsnano.7b06212
   PubMed Web of Science ®Google Scholar
• Kang T, Cho Y, Park C, et al. Effect of biomimetic shear stress on intracellular uptake and cell-killing efficiency of doxorubicin in a free and liposomal formulation. Int J Pharm. 2016;510(1):42–47. doi:10.1016/j.ijpharm.2016.06.017
   PubMedGoogle Scholar
• Fucikova J, Spisek R, Kroemer G, et al. Calreticulin and cancer. Cell Res. 2021;31(1):5–16. doi:10.1038/s41422-020-0383-9
   PubMed Web of Science ®Google Scholar
• Shi Y, van der Meel R, Chen X, et al. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921–7924. doi:10.7150/thno.49577
   PubMed Web of Science ®Google Scholar
• Zhen X, Cheng P, Pu K. Recent advances in cell membrane-camouflaged nanoparticles for cancer phototherapy. Small. 2019;15(1):e1804105. doi:10.1002/smll.201804105
   PubMed Web of Science ®Google Scholar
• An D, Yu X, Jiang L, et al. Reversal of multidrug resistance by apolipoprotein A1-modified doxorubicin liposome for breast cancer treatment. Molecules. 2021;26(5):1280. doi:10.3390/molecules26051280
   PubMed Web of Science ®Google Scholar
• Wang J, Yeung BZ, Cui M, et al. Exosome is a mechanism of intercellular drug transfer: application of quantitative pharmacology. J Control Release. 2017;268:147–158. doi:10.1016/j.jconrel.2017.10.020
   PubMed Web of Science ®Google Scholar
• Liu X, Chen Y, Li H, et al. Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior. ACS Nano. 2013;7(7):6244–6257. doi:10.1021/nn402201w
   PubMed Web of Science ®Google Scholar
• Wathiong B, Deville S, Jacobs A, et al. Role of nanoparticle size and sialic acids in the distinct time-evolution profiles of nanoparticle uptake in hematopoietic progenitor cells and monocytes. J Nanobiotechnology. 2019;17(1):62. doi:10.1186/s12951-019-0495-x
   PubMedGoogle Scholar
• Rodriguez PL, Harada T, Christian DA, et al. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science. 2013;339(6122):971–975. doi:10.1126/science.1229568
   PubMed Web of Science ®Google Scholar
• Krueger TEG, Thorek DLJ, Denmeade SR, et al. Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem Cells Transl Med. 2018;7(9):651–663. doi:10.1002/sctm.18-0024
   PubMed Web of Science ®Google Scholar